After trading hours on Thursday (July 25), CannTrust Holdings (NYSE:CTST,TSX:TRST) announced that it has fired CEO Peter Aceto “with cause” and forced Chairman Eric Paul to resign in the wake of an expanding scandal surrounding growing cannabis in unlicensed rooms.

“The investigation into the company’s non-compliance with Health Canada regulations and ancillary matters uncovered new information that has resulted in a determination by the board to terminate with cause CannTrust CEO Peter Aceto,” the company’s statement reads.


The move to relieve Aceto and Paul of their roles came after an investigation by the Globe and Mail found that the pair, along with other high-level executives, were aware that cannabis plants were being grown in rooms that had yet to be licensed by Health Canada.

It was also revealed that employees were told to hang false walls to hide the rooms during routine Health Canada inspections. The Financial Post reported on Wednesday (July 24) that former employees alleged promotional videos featuring Aceto were filmed in front of one of the unlicensed rooms.

CannTrust’s share price has dropped almost 50 percent since July 8, when the company announced that Health Canada had given its Pelham, Ontario facility a non-compliant rating for growing cannabis in the unlicensed rooms from October 2018 to March of this year. CannTrust shares were at C$5 on July 8 and closed at C$2.58 on Thursday; they rose slightly on Friday (July 26), opening at C$2.90.

As a result of the non-compliant rating, thousands of kilograms of CannTrust’s cannabis were put on hold by both Health Canada and the company.

Robert Marcovitch, who was appointed by CannTrust’s board to lead an investigation into the non-compliance issues, will replace Aceto as interim CEO. He has said that the committee will complete the investigation and bring CannTrust into full regulatory compliance.

The company also said it will “fully cooperate with the regulator in an open and transparent manner to resolve these matters fully and expeditiously.” The statement explains that there will be additional operational changes made in the coming days and weeks.

It isn’t yet known what consequences CannTrust may face from the regulatory body, but there is a chance of recall letters, destruction of product and license suspension, former Health Canada inspector Sherry Boordam said in an interview with BNN Bloomberg.

Earlier this month, Health Canada revoked the cannabis license of BC-based cannabis producer Agrima Botanicals after finding the company had engaged in “unauthorized activities” with cannabis. It was the first time the government agency had revoked a cannabis license since it began issuing licenses to companies to produce medical cannabis in 2013.

A CannTrust spokesperson told the Investing News Network that there will be “additional announcements” from the company in the coming weeks.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

NYSE | TSX: ACB

Aurora Cannabis Inc. (“Aurora” or the “Company”) (NYSE: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today has announced today that it has entered into an agreement with a syndicate of underwriters led by BMO Capital Markets and ATB Capital Markets, under which the underwriters have agreed to buy on bought deal basis 12,000,000 units of the Company (the “Units”), at a price of US$10.45 per Unit for gross proceeds of approximately US$125 million (the “Offering”). Each Unit will be comprised of one common share of the Company (a “Common Share”) and one half of one common share purchase warrant of the Company (each full common share purchase warrant, a “Warrant”). Each Warrant will be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 36 months following the closing date of the Offering at an exercise price of US$12.60 per Warrant Share, subject to adjustment in certain events.

Keep reading... Show less

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less